GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Inventory Turnover

RSLS (Reshape Lifesciences) Inventory Turnover : 0.18 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Reshape Lifesciences's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.49 Mil. Reshape Lifesciences's Average Total Inventories for the quarter that ended in Dec. 2024 was $2.70 Mil. Reshape Lifesciences's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.18.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Reshape Lifesciences's Days Inventory for the three months ended in Dec. 2024 was 506.38.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Reshape Lifesciences's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 1.49.


Reshape Lifesciences Inventory Turnover Historical Data

The historical data trend for Reshape Lifesciences's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Inventory Turnover Chart

Reshape Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.83 2.00 1.34 0.85 0.95

Reshape Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.22 0.25 0.28 0.18

Reshape Lifesciences Inventory Turnover Calculation

Reshape Lifesciences's Inventory Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Inventory Turnover (A: Dec. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2024 ) / ((Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count )
=2.949 / ((3.741 + 2.46) / 2 )
=2.949 / 3.1005
=0.95

Reshape Lifesciences's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover (Q: Dec. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Dec. 2024 ) / ((Total Inventories (Q: Sep. 2024 ) + Total Inventories (Q: Dec. 2024 )) / count )
=0.486 / ((2.934 + 2.46) / 2 )
=0.486 / 2.697
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences  (NAS:RSLS) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Reshape Lifesciences's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Dec. 2024 )/Cost of Goods Sold (Q: Dec. 2024 )*Days in Period
=2.697/0.486*365 / 4
=506.38

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Reshape Lifesciences's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=2.697 / 1.805
=1.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Reshape Lifesciences Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
18 Technology Drive, Suite 110, Irvine, CA, USA, 92618
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey director, officer: President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy director 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney director 2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney director 2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt officer: Vice President of Marketing C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022